New technology enhances Absorption Systems’ metabolite identification capabilities

EXTON, Pa.–Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), announced today that the company has incorporated the LTQ Orbitrap XL Hybrid Fourier Transform mass spectrometer into its drug metabolism program. The introduction of the state-of-the-art technology enables more precise identification of drug metabolites and quantification of the most challenging low-level components in complex biological matrices.

“Absorption Systems consistently utilizes the most advanced, proven technologies available to support customers’ drug metabolism and other ADMET programs”

The LTQ Orbitrap XL, developed by Thermo Scientifc, is based on the fast and sensitive LTQ XL™ linear ion trap mass spectrometer and the Orbitrap mass analyzer. This combination results in an instrument with unsurpassed capabilities for metabolite identification, while retaining sensitivity and dynamic range. The LTQ Orbitrap XL can perform quantification of a parent drug in complex biological matrices (from in vitro microsomal incubates to plasma samples generated in the course of an in vivo pharmacokinetic study), while automatically detecting plausible metabolites and acquiring MS(n) data required for their structural elucidation.

Metabolite ID is an important element of Absorption Systems’ drug metabolism program. It is required by regulatory agencies, helps researchers select the most appropriate nonclinical tox species based on exposure to all major human metabolites and predicts unique or disproportionate human metabolites. In addition, metabolite ID highlights metabolic “soft spots” and certain structural features that may predict toxicity of metabolites.

“Absorption Systems consistently utilizes the most advanced, proven technologies available to support customers’ drug metabolism and other ADMET programs,” commented Patrick M. Dentinger, President and CEO of Absorption Systems. “The LTQ Orbitrap XL provides our clients with superior precision, sensitivity and performance when conducting metabolite ID.”

For more information, visit https://www.absorption.com/metabID.

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based tests systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and in San Diego, CA, and serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit https://www.absorption.com.